January 22, 2025 - 03:09

In a significant move within the healthcare sector, BrightSpring Health Services has announced the divestiture of its ResCare Community Living business to Sevita for a substantial $835 million. This strategic decision reflects BrightSpring's commitment to streamline its operations and focus on its core service areas, enhancing its overall business model.
ResCare Community Living has been a vital part of BrightSpring's portfolio, providing essential services to individuals with intellectual and developmental disabilities. The sale to Sevita, a leading provider of specialized health services, is expected to create new opportunities for growth and innovation in the delivery of community living and support services.
The transaction is anticipated to close in the coming months, pending regulatory approvals. Both companies express confidence that the transition will be smooth and beneficial for the clients and communities they serve. Stakeholders are optimistic about the potential positive impact on service quality and accessibility in the community living sector following this acquisition.
July 23, 2026 - 15:06
Good riddance to bundled ‘global’ maternal care billingThe American College of Obstetricians and Gynecologists is welcoming a major shift in how pregnancy and childbirth are billed. For years, the system relied on a single, bundled `global` fee that...
July 22, 2026 - 21:50
West Nile virus found in two mosquito traps in DeKalb County, health officials sayHealth authorities in DeKalb County have confirmed that mosquitoes collected from two separate traps have tested positive for the West Nile virus. The positive samples were identified during...
July 22, 2026 - 08:37
Bradford A&E services downgraded by health watchdogA health watchdog has downgraded the accident and emergency services at Bradford Royal Infirmary following an inspection that uncovered significant concerns. The Care Quality Commission (CQC) found...
July 21, 2026 - 17:42
Rare disease drugmakers try to avoid Trump price cutsPharmaceutical companies that specialize in treatments for rare diseases are scrambling to shield their products from possible price cuts under a potential second Trump administration. During his...